Arax Advisory Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Arax Advisory Partners’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$142K	Buy	5,432 +4,859	+848%	+$113K	﹤0.01%	2482
2026 Q1	$13.5K	Sell	573 -906	-61%	-$23.1K	﹤0.01%	2293
2025 Q4	$43K	Sell	1,479 -5,148	-78%	-$132K	﹤0.01%	1688
2025 Q3	$125K	Buy	6,627 +6,008	+971%	+$94.8K	﹤0.01%	1454
2025 Q2	$8.68K	Buy	619 +567	+1,090%	+$7.95K	﹤0.01%	2027
2025 Q1	$813	Buy	52 +26	+100%	+$366	﹤0.01%	2376
2024 Q4	$363	Sell	26 -718	-97%	-$7.87K	﹤0.01%	2353
2024 Q3	$6.92K	Sell	744 -25	-3%	-$247	﹤0.01%	1565
2024 Q2	$7.15K	Buy	769 +759	+7,590%	+$6.86K	﹤0.01%	1420
2024 Q1	$99	Sell	10 -24	-71%	-$179	﹤0.01%	1290
2023 Q4	$110	Sell	34 -14	-29%	-$38	﹤0.01%	1306
2023 Q3	$255	Hold	48	–	–	﹤0.01%	1272
2023 Q2	$458	Buy	48 +6	+14%	+$67	﹤0.01%	1217
2023 Q1	$462	Buy	42 +8	+24%	+$116	﹤0.01%	1202
2022 Q4	$503	Buy	+34	New	+$594	﹤0.01%	1180

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Arax Advisory Partners's ARQT Position: Q2 2026 in Review

Arax Advisory Partners increased its Arcutis Biotherapeutics (ARQT) stake by 848% in Q2 2026, buying an estimated $113K and bringing the position to 5,432 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #2482.

Arax Advisory Partners first reported a position in ARQT in Q4 2022 and has held it in 15 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Arax Advisory Partners held 5,432 shares of Arcutis Biotherapeutics worth $142K as of Q2 2026.
Arax Advisory Partners bought 4,859 Arcutis Biotherapeutics shares in Q2 2026, an estimated $113K.
Arcutis Biotherapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2482 holding.
Arax Advisory Partners first reported a position in Arcutis Biotherapeutics in Q4 2022 and has held it in 15 quarters since.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.